NLS Other Stockholder Equity from 2010 to 2025

NLSPW Stock  USD 0.01  0  15.83%   
NLS Pharmaceutics Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity will likely drop to about 35.5 M in 2025. During the period from 2010 to 2025, NLS Pharmaceutics Other Stockholder Equity regression line of quarterly data had mean square error of 174.9 T and geometric mean of  17,125,718. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
70.1 M
Current Value
35.5 M
Quarterly Volatility
22.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 124.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of NLS Pharmaceutics AG over the last few years. It is NLS Pharmaceutics' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

NLS Other Stockholder Equity Regression Statistics

Arithmetic Mean24,440,066
Geometric Mean17,125,718
Coefficient Of Variation90.83
Mean Deviation18,415,810
Median12,515,118
Standard Deviation22,198,854
Sample Variance492.8T
Range61.6M
R-Value0.82
Mean Square Error174.9T
R-Squared0.67
Significance0.0001
Slope3,812,904
Total Sum of Squares7391.8T

NLS Other Stockholder Equity History

202535.5 M
202470.1 M
202361 M
202260.9 M
202142.1 M
202020.6 M
201920.6 M

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity70.1 M35.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.